title: [Experimental study of MMP-2 inhibitor treatment of experimental autoimmune myocarditis in Lewis rats].
abstract: OBJECTIVE
  To investigate the inhibitor of matrix metalloproteinase-2 (MMP-2) (2R)-2-[5-[4-[ ethyl-methylamino] phenyl [thiophene-2-sulfonylamino]-3-methylbutyric acid (TISAM) therapeutic effect on experimental autoimmune myocarditis (EAM) in Lewis rats.
  
  
  METHODS
  Treatment protocol of oral administration of 5 mg/kg TISAM once a day for 14 days was performed on EAM Lewis rats. EAM Lewis rats were divided into 3 groups: treatment in early, middle and later stage respectively (n = 20). After experiment at the designate time point, the rats were euthanatized and hearts were harvested. Cardiac inflammatory score, fibrosis score and content, and infiltration of macrophages and T lyminflammatory score, fibrosis score and content, and infiltration of macrophages and T lymphocytes, message RNA (mRNA) expression of matrix metalloproteinase (MMP)-2 and MMP-9 and protein activity of gelatinase were determined.
  
  
  RESULTS
  TISAM treatment in early phase was invalid (treatment started from the creation of the model), treatment in middle and later phase was effective (treatment started from 7 and 14 day after the creation of the model).
  
  
  CONCLUSIONS
  Inhibitor of MMP-2 can block ventricular remodeling in middle stage in EAM Lewis rats. The mechanism maybe alleviate the inflammatory cell cardiac infiltration, decrease the mRNA expression of MMP-2 at transcript level and downregulate gelatinase activity at protein level.
authors.affiliation: The First Department of Cardiovascular Internal Medicine, Chinese PLA General Hospital, China.
authors.forename: Li-Na
authors.initials: LN
authors.lastname: Han
authors.forename: Tie-Ling
authors.initials: TL
authors.lastname: Li
authors.forename: Ya-Jing
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Ting-Shu
authors.initials: TS
authors.lastname: Yang
authors.forename: Yu
authors.initials: Y
authors.lastname: Ding
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D005260:Female; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use*; D009205:Myocarditis / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D013876:Thiophenes / Q000627:therapeutic use*
chemical_list: C500127:(2R)-2-(5-(4-(ethylmethylamino)phenyl)thiophene-2-sulfonylamino)-3-methylbutyric acid; D061965:Matrix Metalloproteinase Inhibitors; D013876:Thiophenes; D020778:Matrix Metalloproteinase 2